Clinical Trial Update: Tumor Necrosis Factor-alpha Inhibition Using Etanercept in Chronic Fatigue Syndrome [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial evaluating the TNF-alpha inhibitor etanercept for Chronic Fatigue Syndrome/Myalgic Encephalomyelitis has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Fatigue Syndrome
• Myalgic Encephalomyelitis

Drugs mentioned

• Etanercept (etanercept)

Snippet

Sponsor: Haukeland University Hospital | Conditions: Chronic Fatigue Syndrome, Myalgic Encephalomyelitis | Phase 2 | Status: TERMINATED